Antoine Papiernik

We pack the right horse.

If we get to products that deliver on their clinical promise, then from the public markets to the pharma acquisitions, the price is going to be here at the end.

So that's a major reason why, a simple reason why I'm optimistic.

Well, you know, what's happening with funding of science in the U.S., I still think it's noise and that things will change.

And there's still so much funding in the U.S.

in comparison to Europe.

But we might as well leverage that as Europeans.

You know, it's like that's one thing we have.

It's like we publish more than both the U.S.

and China.

We have amazing scientists across this vast territory of Europe, Eurovision Europe, of course, including the U.K., Switzerland, etc.,

And I think that's an asset.

And I think right now, particularly because of what's happening in the U.S., I think the science, the funding of science, the importance, the fact that people think that it's important to, even for just sovereignty reasons, to fund European science, I think this is something that we have.

The thing that is an issue right now is that most European countries have funding.

Constraints on budgets that constraint the ability to pay for innovation and, you know, what the Trump administration is saying about, you know, difference in price of product.

The reality, if you're just purely factual, the reality is that European products are reimbursed a fraction of what, you know, they're being reimbursed in the U.S.,

And it's unlikely to be sustainable.

And if I had, you know, we're close to Christmas.

If I had a wish, it would be, you know, it'd be good to pay more for European innovation.

Otherwise, you know, you may lose them.